AlloSite Tx

AlloSite Tx is a biotechnology company focused on the discovery and development of next-generation allosteric small molecule therapeutics. The company utilizes a proprietary platform that integrates computational biology, structural biology, and medicinal chemistry to identify and target novel allosteric sites on high-value, undruggable proteins. By modulating protein function through these distal sites, AlloSite Tx aims to achieve superior selectivity and potency compared to traditional active-site inhibitors. Their initial pipeline is centered on oncology, with programs targeting key signaling nodes like SHP2 and SOS1.